Benzimidazole compound crystal

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C546S273700

Reexamination Certificate

active

08030333

ABSTRACT:
A novel crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof of the present invention is useful for an excellent antiulcer agent.

REFERENCES:
patent: 4628098 (1986-12-01), Nohara et al.
patent: 5840737 (1998-11-01), Phillips
patent: 6462058 (2002-10-01), Fujishima et al.
patent: 6664276 (2003-12-01), Fujishima et al.
patent: 6939971 (2005-09-01), Fujishima et al.
patent: 7339064 (2008-03-01), Fujishima et al.
patent: 7569697 (2009-08-01), Fujishima et al.
patent: 7737282 (2010-06-01), Fujishima et al.
patent: 40 35 455 (1992-05-01), None
patent: 0 174 726 (1986-03-01), None
patent: 0 302 720 (1989-02-01), None
patent: 92/08716 (1992-05-01), None
patent: 96/02535 (1996-02-01), None
patent: 96/17077 (1996-06-01), None
patent: 97/02261 (1997-01-01), None
patent: 98/21201 (1998-05-01), None
patent: 98/22118 (1998-05-01), None
patent: 98/28294 (1998-07-01), None
patent: 99/38512 (1999-08-01), None
patent: 99/38513 (1999-08-01), None
patent: 99/56698 (1999-11-01), None
U.S. Pharmacopia, #23, National Formulary #18 (1995), pp. 1843-1844.
Concise Encyclopedia Chemistry, Translated and revised by Mary Eagleson (1994), Walter de Gruyter: New York, pp. 872-873.
Rouhi, A. Maureen, “The Rigt Stuff”, Journal C&E News (Feb. 24, 2003), pp. 32-35.
Katsuki, H. et al., “Determination of R(+)- and S(−)-Lansoprazole using Chiral Stationary-Phase Liquid Chromatography and Their Enantioselective Pharmacokinetics in Humans”, Pharmaceutical Research, (1996), vol. 13, No. 4, pp. 611-615.
Curin, A. et al., “Study of Crystal Modifications of Lansoprazole using FT-IR Spectroscopy, Soild-State NMR Spectroscopy and FT-Raman Spectroscopy”, Farm vestn (1997), vol. 48, pp. 290-291.
Vrecer, F. et al., “Study of Influence of Temperature and Grinding on the CrystallineState of Lansoprazole”, Farm vestn, (1997), vol. 48, pp. 242-243.
Nagaya, H. et al., “Effects of the Enantiomers of Lansoprazole (AG-1979) on (H+ + K +)-ATPase Activity in Canine Gastric Microsomes and Acid Formation in Isolated Canine Parietal Cells”, Biochemical Pharmacology, (1991), vol. 42, No. 10, pp. 1875-1878.
Hirschowitz, B. et al., “Long-Term Treatment with Lansoprazole for Patients with Zollinger-Ellison Syndrome”, Aliment Pharmacol Ther (1996), vol. 10, pp. 507-522.
Figura, et al., “In-vitro activity of lansoprazole against Helicobacter pylori”, Joumal of Antimicrobial Chemotherapy, vol. 39, 1997, pp. 585-590.
Langtry, et al., “Lansoprazole”, Drugs, vol. 54, No. 3, 1997, pp. 473-500.
Castell, et al., “Efficacy and Safety of lansoprazole in the treatment of erosive reflux esophagitis”, The American Journal of Gastroenterology, vol. 91, No. 9, 1996, pp. 1749-1757.
Zimmermann, et al., “Lansoprazole: a comprehensive review”, Pharmacotherapy, vol. 17, No. 2, 1997, pp. 308-326.
Katsuya, et al., “Lansoprazole reduces preoperative gastric fluid acidity and volume in children”, Can J Anaesth., 1995, vol. 42, No. 6, pp. 467-472.
Borner, et al., “Separation of Lansoprazole Enantiomers in Human Serum by HPLC”, Chromatographia, vol. 47, No. 3/4, Feb. 1998, pp. 171-175.
Arimori, et al., “Pharmacokinetic Differences Between Lansoprazole Enantiomers in Rats”, J. Pharm. Pharmacol., 1998, vol. 50, pp. 1241-1245.
Landes, et al., “Clinical Pharmacokinetics of Lansoprazole”, Clin. Pharmacokinet., 1995, vol. 28, No. 6, pp. 458-470.
“Experimental Organic Chemistry—Principle and Practice”, Blackwell Scientific Publication 1989, pp. 127-132.
“Vogel's Textbook of Practical Organic Chemistry”, Longman Scientific & Technical; Fifth Edition: 1989, pp. 141-142.
Byrn, “Solid State Chemistry of Drugs”, Academic Press, 1982, pp. 10-13.
Opponent's Statement of Case filed in the matter of: Patent Application No. IL 145,996;Teva Pharmaceutical Industries Ltd. vs.Takeda Pharmaceutical Company Limited, Notice of Opposition filed Oct. 6, 2008, Opponent's Statement of Case filed Feb. 6, 2009—14 pages.
Robinson, Malcolm, Annals of Internal Medicine, vol. 124, vol. 10, pp. 859-867, 1996.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Benzimidazole compound crystal does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Benzimidazole compound crystal, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzimidazole compound crystal will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4265575

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.